Skip to main content
OTCMKTS:PKTX

ProtoKinetix Stock Forecast, Price & News

$0.20
-0.01 (-6.20 %)
(As of 05/14/2021 03:14 PM ET)
Add
Compare
Today's Range
$0.17
$0.23
50-Day Range
$0.18
$0.27
52-Week Range
$0.05
$0.27
Volume85,845 shs
Average Volume120,044 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PKTX News and Ratings via Email

Sign-up to receive the latest news and ratings for ProtoKinetix and its competitors with MarketBeat's FREE daily newsletter.


ProtoKinetix logo

About ProtoKinetix

ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company's AFGPs have commercial applications primarily in health care solutions. It develops AAGP to treat dry eye diseases. The company has a collaboration research agreement with the University of British Columbia. The company was formerly known as RJV Network, Inc. and changed its name to ProtoKinetix, Incorporated in July 2003. ProtoKinetix, Incorporated was incorporated in 1999 and is based in Marietta, Ohio.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:PKTX
Previous SymbolNASDAQ:PKTX
CUSIPN/A
Phone+1-304-2995070
EmployeesN/A
Year FoundedN/A

Sales & Book Value

Annual SalesN/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.54 out of 5 stars

Medical Sector

1492nd out of 2,044 stocks

Biotechnology Industry

79th out of 158 stocks

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











ProtoKinetix (OTCMKTS:PKTX) Frequently Asked Questions

What stocks does MarketBeat like better than ProtoKinetix?

Wall Street analysts have given ProtoKinetix a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ProtoKinetix wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ProtoKinetix?

ProtoKinetix saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 2,600 shares, an increase of 116.7% from the March 31st total of 1,200 shares. Based on an average trading volume of 342,100 shares, the days-to-cover ratio is currently 0.0 days.
View ProtoKinetix's Short Interest
.

How has ProtoKinetix's stock price been impacted by Coronavirus?

ProtoKinetix's stock was trading at $0.2123 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PKTX shares have decreased by 8.1% and is now trading at $0.1951.
View which stocks have been most impacted by COVID-19
.

Who are ProtoKinetix's key executives?

ProtoKinetix's management team includes the following people:
  • Mr. Clarence Edward Smith, Chairman, CEO & Pres (Age 57)
  • Mr. Michael Richard Guzzetta CPA, Chief Financial Officer (Age 63, Pay $60k)
  • Dr. Jean-Charles Quirion Ph.D., Head of Researchers for Rouen

Who are some of ProtoKinetix's key competitors?

What other stocks do shareholders of ProtoKinetix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProtoKinetix investors own include Fulcrum Therapeutics (FULC), Rockwell Medical (RMTI), Provention Bio (PRVB), VIVUS (VVUS), Actinium Pharmaceuticals (ATNM), Chimerix (CMRX), (PCSA), Rexahn Pharmaceuticals (REXN), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).

What is ProtoKinetix's stock symbol?

ProtoKinetix trades on the OTCMKTS under the ticker symbol "PKTX."

How do I buy shares of ProtoKinetix?

Shares of PKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProtoKinetix's stock price today?

One share of PKTX stock can currently be purchased for approximately $0.20.

What is ProtoKinetix's official website?

The official website for ProtoKinetix is www.protokinetix.com.

Where are ProtoKinetix's headquarters?

ProtoKinetix is headquartered at 412 Mulberry St, MARIETTA, OH 45750-2016, United States.

How can I contact ProtoKinetix?

ProtoKinetix's mailing address is 412 Mulberry St, MARIETTA, OH 45750-2016, United States. The company can be reached via phone at +1-304-2995070.


This page was last updated on 5/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.